article, take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published. Peter Nash, Iain B. McInnes, Philip J. Mease, Howard Thom, Kunal Gandhi ... , UK, and was funded by Novartis Pharma AG, Basel, Switzerland. Disclosures. Peter Nash has received grant/ research support and consulting fees from Novartis. Iain B. McInnes has received consulting
By Peter Nash Swisher, Published on 06/01/15
research company engaged by (paid by) Merck and Co. to design and conduct the study. Peter Nash is a prior paid consultant of Merck & Co., not paid with respect to the current research. Denis Choquette is a
Introduction Adalimumab, an anti-tumor necrosis factor antibody, is currently available in a 40 mg/0.8 mL formulation. The objective of this analysis was to evaluate injection site-related pain, safety, and tolerability of a 40 mg/0.4 mL formulation of adalimumab that had fewer excipients, a smaller volume, and a delivery presentation with a smaller gauge needle, versus the...
participants at the UAE meeting, which was chaired by Associate Professor Peter Nash, came from Egypt, Libya, Qatar, Saudi Arabia, Tunisia and the UAE, while the 69 participants at the Morocco meeting came from
Stevens 0 Kathleen Morrisroe 0 David Prior Candice Rabusa 0 Peter Youssef Eli Gabbay Janet Roddy Jennifer Walker Jane Zochling Joanne Sahhar Peter Nash Susan Lester Maureen Rischmueller Susanna M Proudman
Cellular therapies are emerging as a standard approach for the treatment of several diseases. However, realizing the promise of cellular therapies across the full range of treatable disorders will require large-scale, controlled, reproducible culture methods. Bioreactor systems offer the scale-up and monitoring needed, but standard stirred bioreactor cultures do not allow for the...
Introduction The aim of the study was to interrogate the genetic architecture and autoimmune pleiotropy of scleroderma susceptibility in the Australian population. Methods We genotyped individuals from a well-characterized cohort of Australian scleroderma patients with the Immunochip, a custom array enriched for single nucleotide polymorphisms (SNPs) at immune loci. Controls were...
Nash 5 16 Susan Lester 5 13 Maureen Rischmueller 5 13 Susanna M Proudman 5 14 Mandana Nikpour 0 1 3 5 6 0 Department of Medicine, St Vincent's Hospital Melbourne, The University of Melbourne , 41
Mandana Nikpour 0 Pravin Hissaria Jillian Byron Joanne Sahhar Maree Micallef William Paspaliaris Janet Roddy Peter Nash Alan Sturgess Susanna Proudman Wendy Stevens 0 The University of Melbourne
NEVADA LAW JOURNAL ST. PAUL FRE & MARINE INS. Co. THE LEGACY OF BIRD V. Peter Nash Swisher 0 0 Professor of Law, University of Richmond Law School; B.A. Amherst College , 1966 Lord Chancellor ... purpose of contract law is to protect the reasonable expectation of persons who become parties to the bargain."). 90 See generally Peter Nash Swisher, A Realistic Consensus Approach to the Insurance Law
See, e.g., Walter Wadlington, Divorce Without Fault Without Perjury THE ALI PRINCIPLES: A FAREWELL TO FAULT-BUT WHAT REMEDY FOR THE EGREGIOUS MARITAL MISCONDUCT OF AN ABUSIVE SPOUSE? PETER NASH ... ” marriage.10 The time has come to shift the focus of national attention from divorce to marriage and to rebuild a family culture based on enduring marital relationships.”). 9. See, e.g., Peter Nash Swisher
Vivek Thakkar 0 Wendy M Stevens 0 David Prior Owen A Moore 0 Jillian Byron 0 Danny Liew Karen Patterson Pravin Hissaria Janet Roddy Jane Zochling Joanne Sahhar Peter Nash Kathleen Tymms David
Christopher P Denton 0 Jerome Avouac Frank Behrens Daniel E Furst Ivan Foeldvari Marc Humbert DoerteHuscher Otylia Kowal-Bielecka Marco Matucci-Cerinic Peter Nash Christian F Opitz David Pittrow
REFORM: WHY VIRGINIA SHOULD ADOPT THE HENDERSON-TWERSKI PROPOSED REVISION OF SECTION 402A, RESTATEMENT (SECOND) OF TORTS Peter Nash Swisher* I. INTRODUCTION Over the past three decades, literally